Revenue increased 23% year-over-year, core operating profit increased 50% year-over-year. Full-year guidance was revised upward: revenue +110 billion yen, core operating profit +80 billion yen. Targeting a 30% core operating profit margin. Pipeline advances include PADCEV, IZERVAY, VYLOY and progress in CTD\/PoC. Positive impact from foreign exchange considered.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4503-20261104-03.pdf","jir_short_summary":"Revenue increased 23% year-over-year, core operating profit increased 50% year-over-year. Full-year guidance was revised upward: revenue +110 billion yen, core operating profit +80 billion yen. Targeting a 30% core operating profit margin. Pipeline advances include PADCEV, IZERVAY, VYLOY and progress in CTD\/PoC. Positive impact from foreign exchange considered.","jir_summary":"### Overview of Results\nIn Fiscal 2026 Q2, revenue was 12,709 hundred million yen (Year-over-Year +23.4%) and core operating profit was 4,249 hundred million yen (Year-over-Year +50.3%), representing significant growth. Growth of key strategic products and cost optimization (SMT) improved SG&A ratio, and FX effects provided a tailwind. Full-year guidance has been revised upward: revenue is expected at 22,200 hundred million yen (+110 hundred million yen) and core operating profit at 6,200 hundred million yen (+80 hundred million yen). Core operating profit margin is expected to be approximately 30%.\n\n### Pipeline Progress and Milestones\nProgress was reported across indications centered on PADCEV, IZERVAY, and VEOZAH, including Phase III, PoC, and clinical stage advancements. Expansion of PADCEV in MIBC and 1L mUC, expanded indication potential for IZERVAY in GA patients, and clinical results for CLDN18.2-related agents such as VYLOY and ASP2138 are notable. New programs will enter Phase I\/II, and PoC achievements and data announcements across multiple items are expected to continue.","jir_financial_highlights":"Revenue: 12,709 (Year-over-Year +23.4%)\nCore Operating Profit: 4,249 (Year-over-Year +50.3%)\nFull-Year Revenue (Guidance): 22,200 (Initial guidance 23,300 \u2192 Revised 23,300 (+1,100))\nFull-Year Core Operating Profit (Guidance): 6,200 (Initial guidance 7,000 \u2192 Revised 7,000 (+800))\nCore Operating Profit Margin: 30.0% (Revised target)","jir_category":"","jir_hashtags":"#ASTELLAS, #Earnings, #FullYearRevision, #Pipeline, #SMT","jir_key_figures":"Revenue: 12,709 hundred million yen (2Q actual, Year-over-Year +23.4%)\nCore Operating Profit: 4,249 hundred million yen (2Q actual, Year-over-Year +50.3%)\nRevised Full-Year Revenue: 22,200 hundred million yen (Initial guidance +1,100 hundred million yen)\nRevised Full-Year Core Operating Profit: 6,200 hundred million yen (Initial guidance +800 hundred million yen)\nCore Operating Profit Margin: 30.0% (Full-year target)","jir_meta_title":"Astellas Pharma Inc. Fiscal 2026 Q2 Results | Significant Increase in Revenue and Core Profit; Full-Year Upward Revision","jir_meta_description":"Summary of Astellas Pharma Inc.'s Fiscal 2026 Q2 results. Revenue rose 23% year-over-year and core operating profit grew over 50%. Full-year guidance revised upward, driven by progress in key strategic products and cost optimization. Key pipeline updates included.","jir_og_title":"Astellas Pharma Inc. Fiscal 2026 Q2 Results | Strong Revenue and Core Profit Growth","jir_og_description":"Overview of Fiscal 2026 Q2 results. Revenue and core operating profit increased substantially, and full-year guidance was revised upward. Summarizes major pipeline progress and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[10301,12709]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[2826,4249]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit Margin\\\",\\\"data\\\":[27.4,33.4]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Contribution by Key Strategic Products\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"PADCEV\\\",\\\"IZERVAY\\\",\\\"VYLOY\\\",\\\"VEOZAH\\\",\\\"XOSPATA\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Fiscal 2026 Q2 Actual\\\",\\\"data\\\":[5339,3339,1583,562,459]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Full-Year Guidance Comparison (Before and After Revision)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Core Operating Profit\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Initial Guidance\\\",\\\"data\\\":[22300,6200]},{\\\"label\\\":\\\"Revised Guidance\\\",\\\"data\\\":[22200,6200]}]}}\"}]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141149","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n